Research
Hormonal
GIP antagonism has been shown to reduce the development of obesity in preclinical models.
GIP antagonism could be a potential strategy for obesity treatment.
StrongSupportsmedium confidence
Both genetic abrogation and immunoneutralization of GIP signaling have been shown to reduce the development of obesity in preclinical models.
Why this rating
The claim is based on experimental findings in preclinical studies.
Source
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
M. Michael Wolfe et al. · Endocrine Reviews · 2025
DOI 10.1210/endrev/bnaf006
reviewCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →